News
-
German biotech startup AATec Medical announced that it has raised €4 million prior to a series A financing, with the funds going to development of the company’s ATL-105 inhaled recombinant alpha-1 antitrypsin (AAT) for the… Read more . . .
-
According to Orexo, a dry powder formulation of an intranasal influenza vaccine formulated with the company’s AmorphOX powder engineering platform has produced a similar immune response in rats compared to a liquid formulation of the… Read more . . .
-
ENA Respiratory has announced that researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health will conduct a Phase 2 study of ENA’s INNA-051 intranasal dry powder TLR2/6 agonist,… Read more . . .
-
Inhaled vaccine developer Ethris and CDMO Lonza have announced that Lonza will develop spray-dried formulations of Ethris mRNA-based vaccine candidates. Earlier this year, Ethris announced that it would receive $5 million from the Coalition for… Read more . . .
-
According to Avalyn Pharma, Phase 1 trials of AP02 inhaled nintedanib demonstrated that all dose levels of the nebulized formulation were safe and well tolerated and that the company now plans to advance AP02 into… Read more . . .
-
The upcoming RDD Europe 2025 conference in Estoril, Portugal will mark the 20th anniversary of the first RDD Europe meeting, which took place in Paris in 2005. Co-organized by RDD Online and Aptar Pharma, the… Read more . . .
-
Nebulizer maker HCmed has announced the appointment of Chris Vernall as its new Executive VP of Business Development. Vernall started his career as an inhalation scientist at Nanopharm and later returned to Nanopharm as Director… Read more . . .
-
According to Iconovo, the European Patent Office has indicated that it will approve a patent application for an additional patent that will provide protection for Iconovo’s ICOres reservoir-based dry powder inhaler platform until 2038. ICOres… Read more . . .
-
Liquidia Corporation announced that FDA has accepted a resubmission of its NDA for Yutrepia dry powder treprostinil for inhalation for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease… Read more . . .
-
Milestone Pharmaceuticals announced that it has received a complete response letter from the FDA in regard to the company’s NDA for Cardamyst etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). Milestone first submitted… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan